pyrroles has been researched along with Koch's Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Altwegg, R; Charpy, F; Debourdeau, A | 1 |
| Abebe, M; Abozen, T; Alabanza, PL; Ameni, G; Aseffa, A; Balcha, TT; Baric, RS; Belay, M; Berg, S; Brown, AJ; Chandran, A; Cohen, MS; Coombs, RW; Degli-Angeli, EJ; Demaret, J; Dong, C; Dragavon, JA; Duke, ER; Eltayeb, O; Eron, JJ; Fang, L; Fischer, WA; Forrest, S; Goecker, EA; Harris, KA; Hong, S; Hudgens, MG; Huggett, JF; Jolliffe, DA; Jones, GM; Keys, J; Krajewski, TJ; Li, B; Li, L; Loftis, AJ; Manwandu, H; Martineau, AR; Martineau, HM; Mayito, J; Mollan, KR; Morse, CG; Nikolayevskyy, V; Noursadeghi, M; O'Sullivan, DM; Painter, W; Premkumar, L; Reece, ST; Sheahan, TP; Shuang, S; Szewczyk, LJ; Tayachew, D; Tegegn, M; Tirfie, EA; Tulu, B; Vordermeier, M; Wang, Q; Wang, X; Wohl, DA; Wolfe, CR; Won, JJ; Younis, S; Zewude, A | 1 |
| Karkara, BB; Kumar, A; Panda, G | 1 |
| Alfonso, S; Ballell, L; Barros Aguirre, D; Bates, RH; Biava, M; Cocozza, M; Consalvi, S; De Logu, A; Fernandez-Menendez, R; Poce, G; Venditti, G; Vistoli, G | 1 |
| An, Q; Chen, L; Ju, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Yang, T; Yang, Y; Zhang, T | 1 |
| Deng, W; Sun, L; Wu, Q; Zhang, Z | 1 |
| Agus, E; Alfonso, S; Ballell, L; Bates, RH; Biava, M; Botta, M; Cocozza, M; De Logu, A; De Rossi, E; Franzblau, SG; La Rosa, V; Manetti, F; Ortega, F; Pasca, MR; Poce, G; Porretta, GC; Rullas, J; Wae, B | 1 |
| Ballante, F; Biava, M; Costi, R; De Vita, D; Di Santo, R; Feroci, M; Friggeri, L; Manetti, F; Musmuca, I; Ragno, R; Scipione, L; Tortorella, S | 1 |
| Aminabhavi, TM; Gadad, AK; Joshi, SD; Kulkarni, VH; More, UA; Nadagouda, MN | 1 |
| Carmona, L; Gomez-Reino, JJ; Maneiro, JR; Salgado, E; Souto, A | 1 |
| Aminabhavi, TM; Joshi, SD; Koli, D; Kulkarni, MS; More, UA; Nadagouda, MN | 1 |
| Cole, ST; Conroy, TM; Hartkoorn, RC; Huszár, S; Kazakova, E; Kolly, GS; Makarov, V; Mikušová, K; Neres, J; Piton, J; Ryabova, OB; Šarkan, M; Vocat, A | 1 |
| Cardiel, MH; Gomez-Reino, JJ; Gul, A; Kwok, K; Lukic, T; Mortensen, E; Park, SH; Ponce de Leon, D; Riese, R; Tanaka, Y; Valdez, H; Winthrop, KL | 1 |
| Dorhoi, A | 1 |
| Ahidjo, BA; Bishai, WR; Bougoudogo, F; Cheung, L; Lun, S; Maiga, M; Maiga, MC; Pelly, S | 1 |
| Arista, L; Boyle, GA; Brunschwig, C; Chibale, K; de Kock, C; Gessner, RK; Lawrence, N; Manjunatha, UH; Moosa, A; Njoroge, M; Rao, SP; Seldon, R; Sirgel, F; Smith, PW; Soares de Melo, C; Street, LJ; Taylor, D; van der Westhuyzen, R; van Helden, P; Warner, DF; Wilson, CR; Winks, S | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Biava, M; Botta, M; De Logu, A; De Rossi, E; Manetti, F; Meleddu, R; Poce, G; Porretta, GC | 1 |
| Alfonso, S; Battilocchio, C; Biava, M; Botta, M; de Logu, A; Manetti, F; Poce, G; Porretta, GC | 1 |
| Aung, H; Hirsch, CS; Toossi, Z; Wu, M | 1 |
| Ammerman, NC; Bishai, WR; Guo, H; Lun, S; Maiga, M; Winglee, K | 1 |
| Anbarasu, A; Jha, DK; Lavanya, P; Panda, L; Ramaiah, S | 1 |
| JENEY, E; ZSOLNAI, T | 1 |
6 review(s) available for pyrroles and Koch's Disease
| Article | Year |
|---|---|
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Topics: Adamantane; Animals; Antitubercular Agents; DNA Gyrase; Drug Development; Enzyme Inhibitors; Humans; Isonicotinic Acids; Mycobacterium tuberculosis; Oxazolidinones; Piperidines; Pyrroles; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant; Uridine | 2021 |
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Asia, Eastern; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3, Human; Humans; Mycobacterium tuberculosis; Piperidines; Prevalence; Pyrimidines; Pyrroles; Recurrence; Risk; Tuberculosis; Virus Activation | 2019 |
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
Topics: Biological Products; Humans; Incidence; Latent Tuberculosis; Piperidines; Pyrimidines; Pyrroles; Risk; Tuberculosis | 2014 |
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Janus Kinase 3; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Tuberculosis | 2016 |
Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
Topics: Animals; Antitubercular Agents; Drug Design; Humans; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship; Tuberculosis | 2011 |
LL-3858.
Topics: Animals; Antitubercular Agents; Humans; Isonicotinic Acids; Pyrroles; Treatment Outcome; Tuberculosis | 2008 |
18 other study(ies) available for pyrroles and Koch's Disease
| Article | Year |
|---|---|
Disseminated Tuberculosis in a Patient Treated with Tofacitinib for Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2022 |
Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoniazid; Latent Tuberculosis; Leukocytes, Mononuclear; Manganese Compounds; Methylene Blue; Microscopy, Confocal; Mycobacterium tuberculosis; Nanocomposites; Nanoparticles; Neoplasms; Oxides; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polyethylene Glycols; Polymers; Prospective Studies; Pyrroles; Tuberculin Test; Tuberculosis; Tumor Microenvironment | 2021 |
In vivo potent BM635 analogue with improved drug-like properties.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship; Tuberculosis | 2018 |
Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Design; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Pyrroles; Serine Endopeptidases; Tuberculosis | 2018 |
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.
Topics: Animals; Antibiotics, Antitubercular; Bacterial Proteins; Cell Line; Female; Humans; Mice; Microbial Sensitivity Tests; Microsomes; Mycobacterium tuberculosis; Piperazines; Pyrroles; Tuberculosis | 2013 |
Pharmacophore assessment through 3-D QSAR: evaluation of the predictive ability on new derivatives by the application on a series of antitubercular agents.
Topics: Antitubercular Agents; Drug Design; Humans; Models, Molecular; Mycobacterium tuberculosis; Oxazolidinones; Pyrroles; Quantitative Structure-Activity Relationship; Tuberculosis | 2013 |
Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Design; Humans; Hydrazones; Ligands; Molecular Docking Simulation; Mycobacterium tuberculosis; Oxidoreductases; Pyrroles; Quantitative Structure-Activity Relationship; Tuberculosis | 2014 |
Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Design; Humans; Models, Molecular; Mycobacterium tuberculosis; Oxidoreductases; Pyrroles; Quantitative Structure-Activity Relationship; Thiadiazoles; Tuberculosis | 2015 |
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Catalytic Domain; Disease Models, Animal; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperazines; Pyridines; Pyrroles; Spiro Compounds; Structure-Activity Relationship; Thiazines; Tuberculosis | 2015 |
Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis.
Topics: Animals; Female; Humans; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2015 |
Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred BALB C; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2015 |
Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.
Topics: Animals; Antitubercular Agents; Electron Transport Complex III; Humans; Mice; Microsomes, Liver; Molecular Targeted Therapy; Mycobacterium tuberculosis; Pyridones; Pyrroles; Rats; Tuberculosis | 2015 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis, and microbiological evaluation.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Models, Molecular; Mycobacterium tuberculosis; Pyrroles; Quantitative Structure-Activity Relationship; Tuberculosis; Vero Cells | 2009 |
Inhibition of Mycobacterium tuberculosis-induced signalling by transforming growth factor-β in human mononuclear phagocytes.
Topics: Benzamides; Dioxoles; Humans; Isoquinolines; Leukocytes, Mononuclear; Mycobacterium tuberculosis; Phagocytes; Plasminogen Activators; Plasminogen Inactivators; Pyridines; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Tuberculosis | 2012 |
Risk of tuberculosis reactivation with tofacitinib (CP-690550).
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Immunologic Factors; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2012 |
Detection and confirmation of alkaloids in leaves of Justicia adhatoda and bioinformatics approach to elicit its anti-tuberculosis activity.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Alkaloids; Antitubercular Agents; Computational Biology; Fatty Acid Synthase, Type II; Humans; Justicia; Molecular Docking Simulation; Mycobacterium tuberculosis; Plant Leaves; Pyrroles; Quinazolines; Tuberculosis | 2012 |
[Search for new tuberculostatics. V. N-aryl derivatives of o-dicarboxylic acid imides].
Topics: Dicarboxylic Acids; Imides; Maleates; Mycobacterium tuberculosis; Pregnenes; Pyrroles; Succinates; Tuberculosis | 1959 |